Sarepta Therapeutics is restructuring and prioritizing its pipeline, resulting in 500 job cuts to save $120m annually by 2026. $300m in non-personnel cost savings is expected from 2026. The focus is on high-impact programmes to meet 2027 financial obligations and update Elevidys label for Duchenne muscular dystrophy treatment.

The company is engaging with the FDA to update the Elevidys label, including adding a black box warning for liver injuries. Sarepta agrees with these changes to resolve label issues and is exploring additional immunosuppression protocols for non-ambulant patients. Restructuring aims to enhance financial flexibility with $400m in annual cost savings.

Despite the cuts, Sarepta will support Duchenne therapies and pause limb-girdle muscular dystrophy gene therapy programs. The company seeks strategic alternatives for discontinued projects. CEO Doug Ingram emphasizes a focused strategy to ensure financial endurance and patient-centric dedication to rare genetic disease treatment.

Ingram states the changes will maintain financial strength and profitability, focusing on ELEVIDYS and PMOs for Duchenne treatment. Sarepta plans to advance its pipeline for rare genetic diseases, primarily using the siRNA platform, while meeting financial obligations. The company aims to remain vibrant and dedicated to improving the lives of those with rare genetic diseases.

Read more at Yahoo Finance: Sarepta Therapeutics to cut 500 jobs amid restructuring